TABLE 3.
Correlations between monocyte counts and clinicopathological factors (categorical and ordinal variables)
| No. | Monocyte Counts Median (Range) | ≤0.4 × 109/L (n = 52) | 0.5–0.6 × 109/L (n = 39) | ≥0.7 × 109/L (n = 33) | P | |
|---|---|---|---|---|---|---|
| Age, y | 0.67 | |||||
| <60 | 69 | 0.5 (0–2.1) | 29 (42.0%) | 18 (26.1%) | 22 (31.9%) | |
| ≥60 | 55 | 0.5 (0.3–1.4) | 23 (41.8%) | 21 (38.2%) | 11 (20.0%) | |
| Ethnicity | 0.86 | |||||
| White | 13 | 0.4 (0.3–0.9) | 7 (53.8%) | 2 (15.4%) | 4 (33.3%) | |
| African American | 12 | 0.55 (0.3–1.1) | 5 (41.7%) | 3 (25.0%) | 4 (33.3%) | |
| Hispanic | 73 | 0.5 (0–2.1) | 30 (41.1%) | 25 (34.2%) | 18 (24.7%) | |
| Asian | 26 | 0.5 (0.1–1.6) | 10 (38.5%) | 9 (34.6%) | 7 (26.9%) | |
| Histology | 0.75 | |||||
| Endometrioid | 60 | 0.5 (0–2.1) | 27 (45.0%) | 18 (30.0%) | 15 (25.0%) | |
| Serous | 26 | 0.5 (0.3–1.2) | 11 (42.3%) | 9 (34.6%) | 6 (23.1%) | |
| Clear cell | 9 | 0.4 (0.3–1.2) | 6 (66.7%) | 0 (0%) | 3 (33.3%) | |
| Other | 29 | 0.6 (0.2–1.1) | 8 (27.6%) | 12 (41.4%) | 9 (31.0%) | |
| Grade | 0.63 | |||||
| 1 | 20 | 0.45 (0.3–2.1) | 10 (50.0%) | 5 (25.0%) | 5 (25.0%) | |
| 2 | 25 | 0.5 (0.1–1.6) | 10 (40.0%) | 10 (40.0%) | 5 (20.0%) | |
| 3 | 79 | 0.5 (0–2.0) | 32 (40.5%) | 24 (30.4%) | 23 (29.1%) | |
| Stage | 0.25 | |||||
| I | 21 | 0.6 (0.3–1.1) | 6 (28.6%) | 9 (42.8%) | 6 (28.6%) | |
| II | 11 | 0.4 (0.2–1.6) | 8 (72.7%) | 1 (9.1%) | 2 (18.2%) | |
| III | 42 | 0.5 (0.3–1.6) | 20 (47.6%) | 13 (31.0%) | 9 (21.4%) | |
| IV | 50 | 0.5 (0–2.1) | 18 (36.0%) | 16 (32.0%) | 16 (32.0%) | |
| Surgical staging | 0.08 | |||||
| No | 22 | 0.6 (0–2.1) | 6 (27.3%) | 7 (31.8%) | 9 (40.9%) | |
| Yes | 102 | 0.5 (0.1–2.0) | 46 (45.1%) | 32 (31.4%) | 24 (23.5%) | |
| PFS, mo | 0.20 | |||||
| <12 | 65 | 0.5 (0–2.1) | 24 (36.9%) | 21 (32.3%) | 20 (30.8%) | |
| ≥12 | 59 | 0.5 (0.2–1.4) | 28 (47.5%) | 18 (30.5%) | 13 (22.0%) | |
| Recurrence site | 0.23 | |||||
| Within the pelvis | 34 | 0.4 (0.2–1.4) | 18 (52.9%) | 9 (26.5%) | 7 (20.6%) | |
| Outside the pelvis | 84 | 0.5 (0–2.1) | 33 (39.3%) | 27 (32.1%) | 24 (28.6%) | |
| No. recurrence site | 0.15 | |||||
| Single | 41 | 0.4 (0.2–1.1) | 21 (51.2%) | 14 (34.1%) | 6 (14.6%) | |
| Multiple | 77 | 0.5 (0–2.1) | 30 (39.0%) | 22 (28.6%) | 25 (32.5%) | |
| Chemotherapy | 0.08 | |||||
| No | 34 | 0.6 (0–2.1) | 11 (32.4%) | 9 (26.5%) | 14 (42.2%) | |
| Yes | 90 | 0.5 (0.1–1.6) | 41 (45.6%) | 30 (33.3%) | 19 (21.1%) | |
| Radiotherapy | 0.99 | |||||
| No | 91 | 0.5 (0–2.0) | 40 (44.0%) | 26 (28.6%) | 25 (27.5%) | |
| Yes | 33 | 0.5 (0.1–2.1) | 12 (36.4%) | 13 (39.4%) | 8 (24.2%) | |
| Surgery for recurrence | 0.78 | |||||
| No | 115 | 0.5 (0–2.1) | 49 (42.6%) | 35 (30.4%) | 31 (27.0%) | |
| Yes | 9 | 0.5 (0.3–0.9) | 3 (33.3%) | 4 (44.4%) | 2 (22.2%) |
Mann-Whitney U test or Kruskal-Wallis test was used for P values. There were 17 cases of missing data for monocyte counts and 9 cases of missing data for recurrence site and the number of recurrence.